The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prompt initiation of durvalumab and tremelimumab treatment for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B.
 
Yu-Yun Shao
Honoraria - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche
Speakers' Bureau - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Lilly; Merck; Ono Pharmaceutical; Roche
Research Funding - AstraZeneca; Roche
Travel, Accommodations, Expenses - Roche
 
Ching-Tso Chen
No Relationships to Disclose
 
Chien Huai Chuang
No Relationships to Disclose
 
Tung-Hung Su
No Relationships to Disclose
 
Ming-Chih Ho
No Relationships to Disclose
 
Tai-Chung Tseng
No Relationships to Disclose
 
Tsung-Hao Liu
Travel, Accommodations, Expenses - Roche
 
Tsung-Che Wu
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Daiichi Sankyo; Janssen; Novartis; Roche
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; IPSEN; MSD Oncology; Roche
Consulting or Advisory Role - AstraZeneca; BeiGene; Genentech/Roche; Ipsen; IQVIA; MSD; Omega Therapeutics, Inc.; Roche
Travel, Accommodations, Expenses - AstraZeneca; Roche
 
Chih-Hung Hsu
Honoraria - Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Ono Pharmaceutical; Roche/Genentech
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Eucure Biopharma (Inst); Ipsen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); MSD (Inst); NGM Biopharmaceuticals (Inst); Nucana (Inst); Ono Pharmaceutical (Inst); Roche/Genentech (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche